Simcyp Posters RSS Feed

Gaohua L et al.

Fri, 25 Nov 2011 00:00:00 GMT

A user-friendly physiologically-based pharmacokinetic (PBPK) brain model and its application in simulating drug disposition in brain. 26th JSSX Annual Meeting Tokyo, Japan 20th-22nd November 2012

Abduljalil K et al.

Mon, 14 Nov 2011 00:00:00 GMT

Predicting the effect of CYP2D6 polymorphism on pharmacodynamic response to metoprolol. PKUK 2011 Durham, UK 9th-11th November 2011

Pade D et al.

Mon, 31 Oct 2011 00:00:00 GMT

A performance evaluation of Simcyp Dog - a fully mechanistic physiologically-based pharmacokinetic dog model - based upon a variety of celecoxib IV and oral formulations. AAPS Annual Meeting Washington, DC, USA 23rd-27th October 2011

Turner D et al.

Mon, 31 Oct 2011 00:00:00 GMT

A mechanistic model for the prediction of human-equilibrium blood-to-plasma concentration ratio (B/P): basic and neutraL drugs. AAPS Annual Meeting Washington, DC, USA 23rd-27th October 2011

Darwich AS et al.

Mon, 31 Oct 2011 00:00:00 GMT

Development and application of an In Silico pharmacokinetic 'post bariatric surgery model' in a morbidly obese population to assess drug absorption and metabolism from the gastrointestinal tract. AAPS Annual Meeting Washington, DC, USA 23rd-27th October 2011

Cubitt HE et al.

Mon, 24 Oct 2011 00:00:00 GMT

An investigation into the prediction of in vivo clearance for a range of aldehyde oxidase substrates using a mechanistic population-based pharmacokinetic model. 17th North American ISSX Meeting Atlanta, GA, USA 16th-20th October 2011

Neuhoff S et al.

Mon, 24 Oct 2011 00:00:00 GMT

P-gp efflux has no impact on dose proportionality of digoxin bioavailability over a dose range of 0.125 to 1.5 mg: the outcome of a new PBPK model, that includes the in vitro transporter information, is consistent with the clinical observations. Annual Congress for Clinical Pharmacology Zurich, Switzerland, 20th-22nd October 2011

Pade D et al.

Sun, 21 Aug 2011 00:00:00 GMT

A performance evaluation of Simcyp Dog - a full mechanistic physiologically based pharmacokinetic dog model - based upon a variety of theophylline IV and oral formulations. 8th World Congress on Alternative & Animal Use in the Life Sciences Montreal, Canada, 21st-25th August 2011

Cubitt HE et al.

Mon, 20 Jun 2011 00:00:00 GMT

Sources of inter-individual variability in IVIVE of clearance. An investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. 3rd Pharm Sci Fair Prague, Czech Republic, 13th-17th June 2011

Harwood M et al.

Mon, 20 Jun 2011 00:00:00 GMT

Prediction of diclofenac pharmacokinetics using earl drug discovery in vitro data in a mechanistic dog physiologicallybased pharmacokinetic model - 'Simcyp Dog'. 3rd Pharm Sci Fair Prague, Czech Republic, 13th-17th June 2011

Gaohua L et al.

Thu, 9 Jun 2011 00:00:00 GMT

A physiologically-based pharmacokinetic (PBPK) brain model and its application in simulating drug disposition in brain. PAGE Meeting 2011 Athens, Greece, 7th-10th June 2011

Machavaram K et al.

Mon, 16 May 2011 00:00:00 GMT

Predicting the effect of interlukin-6, an inflammatory cytokine, on time-dependent reduction of cyclosporine clearance: an application of the Simcyp Population-Based Simulator to suppression of CYP450 by biologics. AAPS National Biotechnology Conference San Francisco, USA, 16th-18th May 2011

Barter ZE et al.

Mon, 25 Apr 2011 00:00:00 GMT

Prediction of differences in pharmacokinetics between Chinese and Caucasian populations using a mechanistic physiologically-based pharmacokinetic model. Asia Pacific ISSX-4 Tainan City, Taiwan, 22nd-26th April 2011

Polak S et al.

Mon, 18 Apr 2011 00:00:00 GMT

Combining in vitro-in-vivo extrapolation (IVIVE) and physiologically-based pharmacokinetics (PBPK) with drug related risk assessment: putting pieces together for a priori assessment of the likelihood of cardiotoxicity. ACoP 2011 Meeting San Diego CA, USA, 3rd-7th April 2011

Machavaram K et al.

Mon, 18 Apr 2011 00:00:00 GMT

Modelling the effect of interleukin-6, an inflammatory cytokine, on time-dependent reduction of cyclosporine clearance: an application of the Simcyp Population-based Simulator to suppression of CYP450 by biologics. ACoP 2011 Meeting San Diego CA, USA, 3rd-7th April 2011

Neuhoff S et al.

Mon, 21 Mar 2011 00:00:00 GMT

Interplay of transport and metabolism in the gut: predictions of drug-drug interactions using physiologically based pharmacokinetic modelling. AAPS Workshop Bethesda MD, USA, 14th-16th March 2011

Rowland-Yeo K et al.

Mon, 21 Mar 2011 00:00:00 GMT

Prediction of OAPP1B1-mediated drug-drug interaction between repaglinide and cyclosporine using physiologically based pharmacokinetic (PBPK) modelling. AAPS Workshop Bethesda MD, USA, 14th-16th March 2011

Darwich AS et al.

Mon, 21 Mar 2011 00:00:00 GMT

Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "advanced dissolution, absorption, metabolism (ADAM)" model. AAPS Workshop Bethesda MD, USA, 14th-16th March 2011

Gaohua Lu et al.

Mon, 21 Mar 2011 00:00:00 GMT

Physiologically-based pharmacokinetics (PBPK) with and without diffusion limited permeability: modelling drug concentration-time profile in brain. AAPS Workshop Bethesda MD, USA, 14th-16th March 2011

Rowland-Yeo K et al.

Wed, 2 Mar 2011 00:00:00 GMT

Prediction of the increase in systematic exposure of paroxetine in patients with renal impairment. 112th ASCPT Meeting Dallas TX, USA, 2nd-5th March 2011

Johnson TN et al.

Wed, 2 Mar 2011 00:00:00 GMT

A bottom-up approach to predicting the pharmacokinetics (PK) of theophylline (theo) and its interaction with fluvoxamine (fluv) in liver cirrhosis. 112th ASCPT Meeting Dallas TX, USA, 2nd-5th March 2011

Ghobadi C et al.

Tue, 1 Feb 2011 00:00:00 GMT

Drug clearance in obese patients: shall we expect variations? National Obesity Forum, Northwest Chapter Obesity Training Day Salford Royal Hospital, Salford, 1st February 2011

Almond L et al.

Tue, 30 Nov 2010 00:00:00 GMT

Simulation of virtual human subjects to investigate the impact of CYP2C19*17/*17 on omeprazole exposure. PSWC / AAPS Meeting New Orleans, USA, 13th-19th November 2010

Pade D et al.

Mon, 1 Nov 2010 00:00:00 GMT

Prediction of Vss and tissue concentration-time profiles for four benzodiazepines using physicochemical, in vitro and experimental data in rat using a mechanistic PBPK model. PSWC / AAPS Meeting New Orleans LA, USA, 13th-19th November 2010

Mishra H et al.

Thu, 16 Sep 2010 00:00:00 GMT

Prediction of human intestinal metabolism of CYP3A substrates using the Advanced, Dissolution, Absorption and Metabolism (ADAM) Model. 11th Annual Simcyp Consortium Meeting Sheffield, UK, 19th-21st September 2010

Pade D et al.

Thu, 16 Sep 2010 00:00:00 GMT

Prediction of Vss and tissue concentration-time profiles for four benzodiazepines using physicochemical, in vitro and experimental data in rat using a mechanistic PBPK model. 11th Annual Simcyp Consortium Meeting Sheffield, UK, 19th-21st September 2010

Gaohua Lu et al.

Thu, 16 Sep 2010 00:00:00 GMT

A time-varying physiologically-based pharmacokinetic model of caffeine during pregnancy. DMDG Meeting Canterbury, UK, 15th-17th September 2010

Salem F et al.

Tue, 1 Jun 2010 00:00:00 GMT

Predicting pharmacokinetics for two NSAIDs commonly used in paediatrics using a physiologically-based model: comparing in vitro data, in vivo data from adults, or their combination as input parameters. CAPKR Annual Research Meeting Manchester, UK, 24th-25th June 2010

Salem F et al.

Thu, 17 Sep 2009 00:00:00 GMT

Comparison of in vitro and in vivo metabolic clearance estimates for the prediction of caffeine and theophylline pharmacokinetics in adults, children and neonates using a physiologically based model. DMDG Meeting Cambridge, UK, 17th September 2009

Polak S et al.

Mon, 14 Sep 2009 00:00:00 GMT

Prediction of human pharmacokinetics following dermal administration: intergration of a skin absorption module to the Simcyp Population-Based ADME Simulator with the aim of avoiding animal studies. 7th World Congress on Alternative & Animal Use in the Life Sciences Rome, Italy, 30th August-3rd September 2009

Neuhoff S et al.

Sun, 8 Feb 2009 00:00:00 GMT

The effect of p-glycoprotein (MDR1/ABCB1) on human gut wall absorption depends on physiochemical characteristics of the drug and dosage formulation; simulation of "fa" for digoxin, quinidine and talinolol. LogP 2009 Zurich, Switzerland, 8th-11th February 2009

Yang J et al.

Fri, 6 Feb 2009 00:00:00 GMT

Comparison of the “well-stirred” gut and the “QGut” models for predicting intestinal first-pass metabolism. DMDG Meeting Stevenage, UK, 6th February, 2009

Salem F et al.

Wed, 26 Nov 2008 00:00:00 GMT

Theoretical assessment of metabolic drug interactions in paediatric population: the impact of age related fractional metabolism (fm) and its disparity between adults and neonates. PKUK Meeting London, UK, 26th-28th November 2008

Rowland-Yeo K et al.

Fri, 24 Oct 2008 00:00:00 GMT

Prediction of time-dependent CYP3A4-mediated in vivo drug-drug interactions from in vitro data using biological information on enzyme turnover implemented within a physiologically based model. 15th North American ISSX Meeting San Diego, USA 12th-16th October 2008
Abstract published in: Drug Metabolism Reviews A184, 40(3), 131-132, 2008

Polak S et al.

Fri, 23 May 2008 00:00:00 GMT

Prediction of the in vivo behaviour of modified release formulations of metoprolol from in vitro dissolution profiles using the ADAM model (Simcyp V8).
10th European ISSX Meeting Vienna, Austria, 18th-21st May 2008
Abstract published in: Drug Metabolism Reviews A72, 40(1), 45-46, 2008

Johnson TN et al.

Fri, 23 May 2008 00:00:00 GMT

Prediction of the increased exposure to drugs in liver cirrhosis: a systems biology approach integrating prior information on disease with in vitro data on drug disposition. 10th European ISSX Meeting
Vienna, Austria, 18th-21st May
Abstract published in: Drug Metabolism Reviews A95, 40(1), 63-64, 2008

Yang J et al.

Thu, 22 May 2008 00:00:00 GMT

Cytochrome P450 turnover: methods for determining rates and implications for the prediction of drug interactions.
2nd Asian Pacific ISSX Meeting Shanghai, China, 11th-13th May 2008
Abstract published in: Drug Metabolism Reviews A93, 40(2), 59, 2008

Neuhoff S et al.

Thu, 22 May 2008 00:00:00 GMT

In vitro-in vivo extrapolation of the clearance of drugs by glucuronidation: scaling factors for recombinant UGT1A1 data.
10th European ISSX Meeting Vienna, Austria, 18th -21st May 2008
Abstract published in: Drug Metabolism Reviews A188, 40(1), 133-134, 2008

Neuhoff S et al.

Thu, 22 May 2008 00:00:00 GMT

Simulation of the effect of P-glycoprotein on drug absorption in the human gastrointestinal tract.
10th European ISSX Meeting Vienna, Austria, 18th-21st May 2008
Abstract published in: Drug Metabolism Reviews A236, 40(1), 169-170, 2008

Perrett HF et al.

Sun, 18 May 2008 00:00:00 GMT

What is the level of expression of CYP2D6 in human liver? Influence of different calibration standards of the estimation of CYP2D6 abundance. 10th European ISSX Meeting Vienna, Austria, 18th-21st May 2008

Crewe HK et al.

Sun, 18 May 2008 00:00:00 GMT

Comparison of the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9: determination of inter system extrapolation factors. 10th European ISSX Meeting
Vienna, Austria, 18th-21st May 2008

Johnson TN et al.

Sun, 9 Mar 2008 00:00:00 GMT

Mechanistic models of human pharmacokinetics to predict the effects of liver cirrhosis on the clearance of nine drugs.
American Conference on Pharmacometrics
Tucson, USA, 9th-12th March 2008

Turner D et al.

Thu, 11 Oct 2007 00:00:00 GMT

Supersaturation properties of poorly soluble weak bases are key factors in determining oral drug absorption: a simulation study of nifedipine using the ADAM model (Simcyp V7.1).
EUFEPS & COST B25 Conference
Athens, Greece, 1st-2nd October 2007

Polak S et al.

Thu, 4 Oct 2007 00:00:00 GMT

Impact of variability in estimates of drug diffusion coefficient on the prediction of fraction absorbed from the gut (fa) using the ADAM model (Simcyp V7.1).
EUFEPS & COST B25 Conference
Athens, Greece, 1st-2nd October 2007

Barter ZE et al.

Thu, 20 Sep 2007 00:00:00 GMT

Experimental considerations in determining Inter System Extrapolation Factors required for prediction of human drug clearance from recombinantly expressed enzymes. DMDG Open Meeting. Cambridge, UK, 2007

Perrett HP et al.

Mon, 25 Jun 2007 00:00:00 GMT

The impact of genetic polymorphism in CYP3A5 on the pharmacokinetics of the mixed CYP3A4/5 substrates midazolam and tacrolimus assessed by clinic ESF-UB Conference Costa Brava, Spain, 2007

Perrett HP et al.

Mon, 25 Jun 2007 00:00:00 GMT

Assessing the relevance of genetic polymorphism in CYP3A5 in the kinetics of midazolam and tacrolimus: the importance of adequate study size. ESF-UB Conference Costa Brava, Spain, 2007

Jamei M et al.

Mon, 25 Jun 2007 00:00:00 GMT

A novel physiologically-based mechanistic model for predicting oral drug absorption: the advanced dissolution, absorption, and metabolism (ADAM) model.
4th WCDATD
Kanazawa, Japan, 20th-22nd June 2007

Yang J et al.

Mon, 25 Jun 2007 00:00:00 GMT

Comparison of the “well-stirred” gut and the “QGut” models for predicting intestinal first-pass metabolism.
4th WCDATD
Kanazawa, Japan, 20th-22nd June 2007

Rowland-Yeo K et al.

Thu, 24 May 2007 00:00:00 GMT

Prediction of in vivo drug interactions from in vitro enzyme kinetic data: time-based versus steady state simulations.
PSWC 2007
Amsterdam, Netherlands, 22nd-25th April 2007

Almond L et al.

Wed, 2 May 2007 00:00:00 GMT

Mechanistic prediction of HIV drug-drug interactions in virtual populations from in vitro enzyme kinetic data: ritonavir and saquinavir. International Workshop on Clinical Pharmacology of HIV Therapy Budapest, Hungary, 16th-18th April 2007

Yang J et al.

Wed, 2 May 2007 00:00:00 GMT

Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time) -based enzyme inhibition.
PSWC 2007
Amsterdam, Netherlands, 22nd-25th April 2007

Jamei M et al.

Wed, 2 May 2007 00:00:00 GMT

Bias in estimates of metabolic constants when applying the Michaelis-Menten equation to drugs exhibiting atypical enzyme kinetics.
PSWC 2007
Amsterdam, Netherlands, 22nd-25th April 2007

Almond LM et al.

Sun, 1 Oct 2006 00:00:00 GMT

Prediction of the oral clearance of tolbutamimde in individuals with different CYP2C9 genotypes using in vitro enzyme kinetic data.
14th North American ISSX Meeting
Rio Grande, Puerto Rico, 22nd-26th October 2006
Abstract published in: Drug Metabolism Reviews A323, 38(S2), 209-210, 2006

Barter ZE et al.

Sun, 1 Oct 2006 00:00:00 GMT

Prediction of the oral clearance of midazolam using in vitro data from recombinantly expressed enzymes and inter system extrapolation factors. 14th North American ISSX Meeting Rio Grande, Puerto Rico, 22nd-26th October 2006
Abstract published in: Drug Metabolism Reviews
A71, 38(S2), 41, 2006

Barter ZE et al.

Fri, 1 Sep 2006 00:00:00 GMT

A meta-analysis of CYP3A4 abundance in human liver: use of different standards contributes to apparent heterogeneity in reported values. 35th ACCP Meeting Cambridge MA, USA, 17th-19th September 2006
Abstract published in: Journal of Clinical Pharmacology A82, 46(9), 1080, 2006

Ozdemir M et al.

Fri, 1 Sep 2006 00:00:00 GMT

The impact of dose-staggering on the inhibitory effect of ketoconazole on midazolam clearance, and its prediction using PBPK modelling.
35th ACCP Meeting Cambridge MA, USA, 17th-19th September 2006
Abstract published in: Journal of Clinical Pharmacology A18, 46(9), 1065, 2006

Johnson TN et al.

Fri, 1 Sep 2006 00:00:00 GMT

Prediction of metabolic drug clearance in pediatric subjects and its sensitivity to different models for the development of CYP enzymes.
35th ACCP Meeting Cambridge MA, USA, 17th-19th September 2006
Abstract published in: Journal of Clinical Pharmacology A40, 46(9), 1070, 2006

Almond LM et al.

Fri, 1 Sep 2006 00:00:00 GMT

Utility of data from recombinant expressed genetic variants of CYPs in predicting the influence of genotype on in vivo drug kinetics - the case for S-Warfarin.
35th ACCP Meeting Cambridge MA, USA, 17th-19th September 2006
Abstract published in: Journal of Clinical Pharmacology A27, 46(9), 1067, 2006

Dickinson GL et al.

Fri, 1 Sep 2006 00:00:00 GMT

Assessing the propagation of CYP2C9 polymorphism into the PK/PD of warfarin using clinical trial simulations (CTS).
35th ACCP Meeting Cambridge MA, USA, 17th-19th September 2006
Abstract published in: Journal of Clinical Pharmacology A28, 46(9), 1067, 2006

Turner DB et al.

Thu, 1 Jun 2006 00:00:00 GMT

Prediction of non-specific hepatic microsomal binding from readily available physicochemical properties.
9th European ISSX Meeting
Manchester, UK, 4th-7th June 2006
Abstract published in: Drug Metabolism Reviews A231, 38(1), 162, 2006

Dickinson GL et al.

Thu, 1 Jun 2006 00:00:00 GMT

The propagation of genetic polymorphism in CYP2C9 into tolbutamide pharmacokinetics: assessment using an intergrated model.
9th European ISSX Meeting
Manchester, UK, 4th-7th June 2006
Abstract published in: Drug Metabolism Reviews A206, 38(1), 148, 2006

Heydari A et al.

Thu, 1 Jun 2006 00:00:00 GMT

Predicting drug interactions with selective serotonin reuptake Inhibitors (SSRIs): impact of non-specific binding and active uptake.
9th European ISSX Meeting
Manchester, UK, 4th-7th June 2006
Abstract published in: Drug Metabolism Reviews A100, 38(1), 79, 2006

Almond LM et al.

Thu, 1 Jun 2006 00:00:00 GMT

Prediction of the oral clearance of S-warfarin in CYP2C9 genotypes from in vitro enzyme kinetic data.
9th European ISSX Meeting
Manchester, UK, 4th-7th June 2006
Abstract published in: Drug Metabolism Reviews A121, 38(1), 92-93, 2006

Barter ZE et al.

Thu, 1 Jun 2006 00:00:00 GMT

Differences in cytochrome P450 (CYP3A4) expression alone do not explain inter-individual variability in CYP3A mediated hepatic testosterone 6ß hydroxylase (TST6ßOH) activity.
9th European ISSX Meeting
Manchester, UK, 4th-7th June 2006
Abstract published in: Drug Metabolism Reviews A129, 38(1), 98, 2006

Ozdemir M et al.

Thu, 1 Jun 2006 00:00:00 GMT

The impact of dose-staggering on the inhibitory effect of ketoconazole on midazolam clearance, and its prediction using physiologically-based pharmacokinetic modelling.
9th European ISSX Meeting
Manchester, UK, 4th-7th June 2006
Abstract published in: Drug Metabolism Reviews A103, 38(1), 81, 2006

Jamei M et al.

Thu, 1 Jun 2006 00:00:00 GMT

Co-operativity in the in vitro kinetics of cytochrome P450 (CYP) mediated drug metabolism will have minimal impact on in vivo metabolic clearance.
9th European ISSX Meeting
Manchester, UK, 4th-7th June 2006
Abstract published in: Drug Metabolism Reviews A127, 38(1), 14, 2006

Van LM et al.

Thu, 1 Jun 2006 00:00:00 GMT

Estimation of the kinetic parameters of mechanism-based inhibition of CYP2D6 by methylenedioxymethamphetamine (MDMA) in cryopreserved human hepatocytes.
9th European ISSX Meeting
Manchester, UK, 4th-7th June 2006
Abstract published in: Drug Metabolism Reviews A193, 38(1), 140-141, 2006

Yang J et al.

Thu, 1 Jun 2006 00:00:00 GMT

In-vitro stability of human recombinant cytochrome P450 enzymes.
9th European ISSX Meeting
Manchester, UK, 4th-7th June 2006
Abstract published in: Drug Metabolism Reviews A135, 38(1), 102, 2006

Rowland-Yeo K et al.

Thu, 1 Jun 2006 00:00:00 GMT

Prediction of the inhibitory effects of ketaconazole and fluconazole on midazolam and zolpidem clearance from in vitro data using physiologically-based pharmacokinetic modelling.
9th International Conference on Drug-Drug Interactions Seattle WA, USA, 20th-21st June 2006

Johnson TN et al.

Thu, 1 Jun 2006 00:00:00 GMT

Modelling of the age related changes of human CYP enzymes for predicting drug disposition in neonates, infants and children.
9th European ISSX Meeting
Manchester, UK, 4th-7th June 2006
Abstract published in: Drug Metabolism Reviews A84, 38(1), 20-21, 2006

Perrett HF et al.

Thu, 1 Jun 2006 00:00:00 GMT

The use of recombinantly expressed standards for immuno-quantification of hepatic CYP3A5 can result in an underprediction of CYP3A5 abundance.
9th European ISSX Meeting
Manchester, UK, 4th-7th June 2006
Abstract published in: Drug Metabolism Reviews A146, 38(1), 109, 2006

Van LM et al.

Thu, 1 Jun 2006 00:00:00 GMT

Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine (MDMA): differences between expressed enzyme systems and human liver microsomes.
9th European ISSX Meeting
Manchester, UK, June 4th-7th June 2006
Abstract published in: Drug Metabolism Reviews A54, 38(1), 45, 2006

Barter ZE et al.

Sun, 1 Jan 2006 00:00:00 GMT

Values of human hepatocellularity per gram of liver and associated variability for use in the prediction of human in vitro metabolic clearance.
HUG Meeting
Copenhagen, Denmark, 26th-27th January 2006

Dickinson GL et al.

Tue, 1 Nov 2005 00:00:00 GMT

Simulations to assess the propagation of the impact of genetic polymorphism
in CYP enzymes into PK and PD outcomes: warfarin and dextromethorphan
as examples. AAPS Meeting 2005
Nashville TN, USA, 6th-10th November 2005

Shiran MR et al.

Wed, 1 Jun 2005 00:00:00 GMT

Prediction of xenobiotic clearance in humans: in vitro-in vivo extrapolation (IVIVE) vs allometric scaling (AS).
1st PharmSciFair
Nice, France 12th-17th June 2005

Lei Y et al.

Wed, 1 Jun 2005 00:00:00 GMT

Inter-individual variability in the catalytic activity of CYP3A4 per unit of
enzyme (kcat).
1st PharmSciFair
Nice, France 12th-17th June 2005

Ghanbari F et al.

Wed, 1 Jun 2005 00:00:00 GMT

A critical evaluation of the experimental design in reports of mechanism based inhibition (MBI) studies and the assessment of their implication for in vitro-in vivo extrapolation (IVIVE).
1st PharmSciFair
Nice, France 12th-17th June 2005

Wilson ZE et al.

Wed, 1 Jun 2005 00:00:00 GMT

Implications of the disparity in relative holo:apo-protein contents of different standards used for immuno-quantification of hepatic P450 3A4 (CYP3A4).
1st PharmSciFair
Nice, France 12th-17th June 2005

Howgate EM et al.

Wed, 1 Jun 2005 00:00:00 GMT

Incorporation of inter-individual variability into the prediction of in vivo
drug clearance.
1st PharmSciFair
Nice, France 12th-17th June 2005

Jamei M et al.

Wed, 1 Jun 2005 00:00:00 GMT

Genetic algorithms and their applications in PK/PD data analysis.
1st PharmSciFair
Nice, France, 12th-17th June 2005

Heydari A et al.

Wed, 1 Jun 2005 00:00:00 GMT

The impact of study design on the estimation of parameters describing mechanism-based enzyme inhibition.
1st PharmSciFair
Nice, France 12th-17th June 2005

Dickinson GL et al.

Wed, 1 Jun 2005 00:00:00 GMT

The propagation of genetic polymorphism in CYP2C9 into warfarin pharmacokinetics: an integrated model.
1st PharmSciFair
Nice, France 12th-17th June 2005

Jamei M et al.

Fri, 1 Apr 2005 00:00:00 GMT

Inter- and intra-individual variability in gastro-intestinal physiology has significant effects on the prediction of fraction of dose absorbed (fa).
3rd WCDATD Barcelona, Spain, 18th-20th April 2005

Jamei M

Wed, 17 Nov 2004 00:00:00 GMT

Genetic algorithms and their applications in PK/PD data analysis
Pharmacokinetics UK 2004 Belfast, UK, 17th-18th November 2004

Jamei M et al.

Sun, 29 Feb 2004 00:00:00 GMT

Inter and intra-individual variability in physiological parameters of gastro-intestinal tract has significant effects on the predicted fraction of dose absorbed.
LogP 2004 Zurich, Switzerland, 29th February-4th March 2004

Yang J & Rostami-Hodjegan A

Sun, 1 Feb 2004 00:00:00 GMT

Accounting for first pass gut metabolism improves the relationship between lipophilicity and in vivo permeability.
LogP 2004 Zurich, Switzerland, 29th February-4th March 2004

Howgate EM et al.

Sun, 1 Jun 2003 00:00:00 GMT

Prediction drug clearance allowing for the influence of P-glycoprotein activity using SIMCYP.
The Proceedings of the 6th Congress of European Association for Clinial Pharmacology and Therapeutics
152, June 24th-28th 2003, Istanbul

Proctor NJ et al.

Sat, 1 Jun 2002 00:00:00 GMT

Population clearance prediction of 13 drugs using SIMCYP.
Pharmacologist 44 (Supplement 1), LB87, 2002

Boyle J et al.

Sun, 1 Jul 2001 00:00:00 GMT

Reference values for human microsomal protein per gram of liver. Proceedings of the British Pharmacological Society July 3rd-5th 2001, Clinical Pharmacology Section, University College, Dublin.
Abstract published in: British Journal of Clinical Pharmacology A10, 52(4), 471, 2001

Yang JS et al.

Sun, 1 Jul 2001 00:00:00 GMT

Prediction of fluconazole interaction with midazolam and triazolam: Incorporating population variability. Proceedings of the British Pharmacological Society July 3rd-5th 2001, Clinical Pharmacology Section, University College, Dublin.
Abstract published in: British Journal of Clinical Pharmacology A26, 52(4), 484, 2001

Rostami-Hodjegan A et al.

Wed, 1 Nov 2000 00:00:00 GMT

Incorporating interindividual variability into in vitro–in vivo extrapolation.
7th EUFEPS Conference
Optimising Drug Development: Strategies to Assess Drug Metabolism/Transport Interaction Potential – Towards a Consensus
November 13th-15th 2000, Basel, Switzerland

Rostami-Hodjegan A

Thu, 1 Jul 1999 00:00:00 GMT

Incorporating variability into prediction of drug-drug interactions: moving from deterministic to a stochastic approach.
Mathematics in Medicine Initiative (MiMI), Compartmental Modelling and Pharmacokinetic Analysis
July 20th-22nd 1999, University of Warwick, United Kingdom.

Tucker GT & Rostami-Hodjegan A

Fri, 1 Aug 1997 00:00:00 GMT

Metabolic variability in populations.
In: The Population Approach: measuring and managing variability in response, concentration and dose.
ECSC-EC-EAE 9-13, Brussels, Luxembourg, 1997.

Tucker GT et al.

Tue, 1 Aug 1995 00:00:00 GMT

Phenotyping populations: pharmacokinetic and statistical issues. In: Variability and Specificity in Drug Metabolism.
(Eds. Alvan G, Balant LP, Bechtel PR et al.)
ECSC-EC-EAE 191-203, Brussels, Luxembourg, 1995

Tucker GT et al.

Tue, 1 Aug 1995 00:00:00 GMT

The determination of drug metabolising status in vivo: pharmacokinetic and statistical issues.
In: Advances in Drug Metabolism in Man.
(Eds. Pacifies GM & Fracchia GN)
ECSC-EC-EAE 37-55, Brussels, Luxembourg, 1995

Jackson PR et al.

Wed, 1 Aug 1990 00:00:00 GMT

Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism – statistical methods. In: Proceedings of European Consensus Conference on Pharmacogenetics. (Eds. Alvan G et al.) ECSC-EC-EAE 43-52, Brussels, Luxembourg, 1990

Tucker GT et al.

Wed, 1 Aug 1990 00:00:00 GMT

Pharmacokinetic-pharmacogenetic modeling – a basis for the display and detection of polymorphisms in drug metabolism. In: Proceedings of European Consensus Conference on Pharmacogenetics. (Eds. Alvan G et al.) ECSC-EC-EAE 59-67 Brussels, Luxembourg, 1990